Pieris Pharmaceuticals Inc. [NASDAQ: PIRS] price plunged by -10.14 percent to reach at -$0.21. The company report on April 26, 2021 that Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific.
Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties.
Boston Pharmaceuticals will be primarily responsible for development of the program, with both parties collaborating during the investigational new drug (IND)-enabling stage.
A sum of 2013354 shares traded at recent session while its average daily volume was at 589.70K shares. Pieris Pharmaceuticals Inc. shares reached a high of $2.08 and dropped to a low of $1.70 until finishing in the latest session at $1.86.
Guru’s Opinion on Pieris Pharmaceuticals Inc. [PIRS]:
Robert W. Baird have made an estimate for Pieris Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 13, 2020. The new note on the price target was released on July 30, 2019, representing the official price target for Pieris Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $5, while Robert W. Baird analysts kept a Outperform rating on PIRS stock.
The Average True Range (ATR) for Pieris Pharmaceuticals Inc. is set at 0.18, with the Price to Sales ratio for PIRS stock in the period of the last 12 months amounting to 3.88. The Price to Book ratio for the last quarter was 3.38, with the Price to Cash per share for the same quarter was set at 1.15.
PIRS Stock Performance Analysis:
Pieris Pharmaceuticals Inc. [PIRS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.70. With this latest performance, PIRS shares dropped by -29.01% in over the last four-week period, additionally sinking by -26.48% over the last 6 months – not to mention a drop of -27.91% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PIRS stock in for the last two-week period is set at 31.21, with the RSI for the last a single of trading hit 24.83, and the three-weeks RSI is set at 35.24 for Pieris Pharmaceuticals Inc. [PIRS]. The present Moving Average for the last 50 days of trading for this stock 2.4860, while it was recorded at 2.0860 for the last single week of trading, and 2.6496 for the last 200 days.
Insight into Pieris Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pieris Pharmaceuticals Inc. [PIRS] shares currently have an operating margin of -115.68. Pieris Pharmaceuticals Inc.’s Net Margin is presently recorded at -126.97.
Return on Total Capital for PIRS is now -58.71, given the latest momentum, and Return on Invested Capital for the company is -65.43. Return on Equity for this stock declined to -90.39, with Return on Assets sitting at -30.26. When it comes to the capital structure of this company, Pieris Pharmaceuticals Inc. [PIRS] has a Total Debt to Total Equity ratio set at 54.67. Additionally, PIRS Total Debt to Total Capital is recorded at 35.35, with Total Debt to Total Assets ending up at 16.15. Long-Term Debt to Equity for the company is recorded at 51.35, with the Long-Term Debt to Total Capital now at 33.20.
Reflecting on the efficiency of the workforce at the company, Pieris Pharmaceuticals Inc. [PIRS] managed to generate an average of -$302,683 per employee. Receivables Turnover for the company is 6.91 with a Total Asset Turnover recorded at a value of 0.24.Pieris Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.40.
PIRS Stock EPS
With the latest financial reports released by the company, Pieris Pharmaceuticals Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 58.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PIRS.
Pieris Pharmaceuticals Inc. [PIRS] Insider Position Details
There are presently around $69 million, or 64.40% of PIRS stock, in the hands of institutional investors. The top three institutional holders of PIRS stocks are: BVF INC/IL with ownership of 5,494,582, which is approximately 0% of the company’s market cap and around 12.29% of the total institutional ownership; AQUILO CAPITAL MANAGEMENT, LLC, holding 3,675,530 shares of the stock with an approximate value of $7.61 million in PIRS stocks shares; and BLACKROCK INC., currently with $7.52 million in PIRS stock with ownership of nearly 1.901% of the company’s market capitalization.
Positions in Pieris Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 37 institutional holders increased their position in Pieris Pharmaceuticals Inc. [NASDAQ:PIRS] by around 2,210,690 shares. Additionally, 29 investors decreased positions by around 1,746,389 shares, while 26 investors held positions by with 29,449,900 shares. The mentioned changes placed institutional holdings at 33,406,979 shares, according to the latest SEC report filing. PIRS stock had 10 new institutional investments in for a total of 692,423 shares, while 10 institutional investors sold positions of 408,885 shares during the same period.